These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 1337430

  • 1. An adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine.
    Kiura K, Ohnoshi T, Ueoka H, Takigawa N, Tabata M, Segawa Y, Shibayama T, Kimura I.
    Anticancer Drug Des; 1992 Dec; 7(6):463-70. PubMed ID: 1337430
    [Abstract] [Full Text] [Related]

  • 2. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
    Moritaka T, Kiura K, Ueoka H, Tabata M, Segawa Y, Shibayama T, Takigawa N, Ohnoshi T, Harada M.
    Anticancer Res; 1998 Dec; 18(2A):927-33. PubMed ID: 9615743
    [Abstract] [Full Text] [Related]

  • 3. [Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines].
    Takigawa N, Ohnoshi T, Ueoka H, Yonei T, Kiura K, Tabata M, Kodani T, Kamei H, Segawa Y, Shibayama T.
    Gan To Kagaku Ryoho; 1993 May; 20(7):929-35. PubMed ID: 8387762
    [Abstract] [Full Text] [Related]

  • 4. An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line.
    Kiura K, Watarai S, Ueoka H, Tabata M, Gemba K, Aoe K, Yamane H, Yasuda T, Harada M.
    Anticancer Res; 1998 May; 18(4C):2957-60. PubMed ID: 9713491
    [Abstract] [Full Text] [Related]

  • 5. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N.
    Cancer Res; 1989 Aug 01; 49(15):4098-102. PubMed ID: 2472873
    [Abstract] [Full Text] [Related]

  • 6. [Establishment of adriamycin-resistant human small-cell lung cancer cells in culture: analysis of the mechanism of resistance and cross-resistance].
    Kimura I, Ohnoshi T, Hiraki S, Miyamoto H.
    Gan To Kagaku Ryoho; 1987 Mar 01; 14(3 Pt 2):830-6. PubMed ID: 3032107
    [Abstract] [Full Text] [Related]

  • 7. The in vitro effects of lonidamine combined with cisplatin in human small cell lung cancer cell lines.
    Ko D, Raaphorst GP, Feeley MM, Danjoux CE, Maroun JA, Evans WK.
    Anticancer Res; 1991 Mar 01; 11(1):235-9. PubMed ID: 1850216
    [Abstract] [Full Text] [Related]

  • 8. In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines.
    Ikubo S, Takigawa N, Ueoka H, Kiura K, Tabata M, Shibayama T, Chikamori M, Aoe K, Matsushita A, Harada M.
    Anticancer Res; 1999 Mar 01; 19(5B):3985-8. PubMed ID: 10628341
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N, Lam YM, Pym J, Campling BG.
    Cancer; 1996 May 01; 77(9):1797-808. PubMed ID: 8646677
    [Abstract] [Full Text] [Related]

  • 10. Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines.
    Takigawa N, Ohnoshi T, Ueoka H, Kiura K, Kimura I.
    Acta Med Okayama; 1992 Aug 01; 46(4):249-56. PubMed ID: 1442149
    [Abstract] [Full Text] [Related]

  • 11. [Assessment of antitumor activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer].
    Takigawa N, Ohnoshi T, Ueoka H, Horiguchi T, Kiura K, Tabata M, Segawa Y, Shibayama T, Genba K, Matsumura T.
    Gan To Kagaku Ryoho; 1993 Jul 01; 20(9):1221-6. PubMed ID: 8392827
    [Abstract] [Full Text] [Related]

  • 12. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
    Twentyman PR, Wright KA, Mistry P, Kelland LR, Murrer BA.
    Cancer Res; 1992 Oct 15; 52(20):5674-80. PubMed ID: 1327513
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin.
    Hong WS, Jung HY, Yang SK, Kim HR, Min YI.
    Anticancer Res; 1997 Oct 15; 17(5A):3613-6. PubMed ID: 9413212
    [Abstract] [Full Text] [Related]

  • 14. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA, Herman TS, Holden SA, Epelbaum R, Liu SD, Frei E.
    Cancer Res; 1991 Feb 01; 51(3):780-4. PubMed ID: 1988117
    [Abstract] [Full Text] [Related]

  • 15. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
    Lee YS, Nishio K, Ogasawara H, Funayama Y, Ohira T, Saijo N.
    Cancer Res; 1995 Mar 01; 55(5):1075-9. PubMed ID: 7866991
    [Abstract] [Full Text] [Related]

  • 16. [In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines].
    Takigawa N, Ohnoshi T, Ueoka H, Kiura K, Moritaka T, Tabata M, Segawa Y, Shibayama T, Gemba K, Matsumura T.
    Gan To Kagaku Ryoho; 1993 Mar 01; 20(4):473-7. PubMed ID: 8383949
    [Abstract] [Full Text] [Related]

  • 17. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
    Lai SL, Hwang J, Perng RP, Whang-Peng J.
    Oncol Res; 1995 Mar 01; 7(1):31-8. PubMed ID: 7549042
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
    Parajuli P, Yano S, Nishioka Y, Nokihara H, Hanibuchi M, Nishimura N, Utsugi T, Sone S.
    Oncol Res; 1999 Mar 01; 11(5):219-24. PubMed ID: 10608616
    [Abstract] [Full Text] [Related]

  • 19. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro.
    Ning SC, Hahn GM.
    Cancer Res; 1990 Dec 15; 50(24):7867-70. PubMed ID: 2253227
    [Abstract] [Full Text] [Related]

  • 20. The effect of lonidamine alone and in combination with cisplatin on in vitro growth and viability of lung squamous cell carcinoma cell lines.
    Raaphorst GP, Ko D, Feeley MM, Danjoux CE, Maroun J, Evans WK.
    Anticancer Res; 1991 Dec 15; 11(1):41-7. PubMed ID: 2018379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.